Agilent Technologies Inc vs Meta Platforms Inc — how do they compare? Agilent Technologies Inc trades at $149.35 (market cap $42.00B), while Meta Platforms Inc trades at $600.11 (market cap $1.52T). The key difference: Meta Platforms Inc is far larger — about 36.2× Agilent Technologies Inc's market cap, and Agilent Technologies Inc pays the higher dividend (0.69%). Which is the better fit depends on your goals.
| A | META | |
|---|---|---|
Market Cap | $42.00B | $1.52T |
Sector | Health | Media |
52-Week High | $157.20 | $790.00 |
52-Week Low | $110.24 | $525.72 |
Enterprise Value | $43.55B | $1.54T |
Dividend Yield | 0.69% | 0.35% |
Volume | — | 24,093,972 |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.
The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.
META stock trades at $594.92, up 0.48% over 24 hours, with a bearish technical signal driven by moving averages and overbought short-term RSI. The company reported strong Q1 2026 earnings of $10.44 EPS, beating expectations, but missed in Q2 2026. Revenue growth remains robust, with 2025 revenue at $200.97 billion, though net income dipped to $60.46 billion. Recent news highlights the launch of AI model Muse Spark and a legal ruling in Massachusetts over youth addiction claims.
Outlook is mixed: analyst consensus is bullish with a $761.95 price target, citing AI innovations and solid fundamentals, but risks include high capital expenditure, regulatory lawsuits, and competitive pressures. The stock's valuation metrics like P/E of 22.41 suggest room for growth if execution continues, but investors should weigh legal and market volatility concerns.
Trailing returns across standard periods
Latest headlines on both assets
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →